Date: Wednesday 22 June
This symposium will give an update on the latest neuroimaging research in psychosis, how these methods can be used to identify treatment targets and the neurobiology behind the effectiveness of clozapine. Dr Beck will explore the possible role of glutamatergic abnormalities in first episode psychosis, by presenting a study of N-Methyl-D-Aspartate Receptor binding in the hippocampus and its association with striatal glutamate using the PET ligand [18F]GE179 and magnetic resonance spectroscopy. Dr Nour will outline recent work that identifies abnormalities in spontaneous memory reactivations (replay) in patients with schizophrenia, and the relationship to cognitive impairments, using magnetoencephalography resting state data. This new evidence provides an insight into neural processes that might contribute to the generation of symptoms including delusions, in addition to highlighting potential neural biomarker of relevance to cognitive symptoms. Professor Howes will speak about the role of glutamate dysfunction in Treatment Resistant Schizophrenia (TRS) and the biological mechanisms that underpin the success of clozapine in these patients. He will outline the emerging approaches to developing new treatment targets using examples from studies conducted in patients with schizophrenia.
Chair: Dr Katherine Beck, King's College London and Professor Oliver Howes, King's College London
The association between N-Methyl-D-Aspartate receptor availability and glutamate levels: a multi-modal PET-MR brain imaging study in first episode psychosis
Dr Katherine Beck, King's College London
Measuring offline replay in schizophrenia and the potential relevance for cognition
Dr Matthew Nour, Max Planck University College London Centre for Computational Psychiatry and Ageing Research
What underlies treatment response in schizophrenia?
Professor Oliver Howes, King's College London